These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 21658851

  • 1. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e593-9. PubMed ID: 21658851
    [Abstract] [Full Text] [Related]

  • 2. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1484-93. PubMed ID: 15590179
    [Abstract] [Full Text] [Related]

  • 3. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):427-36. PubMed ID: 15380576
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K.
    Jpn J Clin Oncol; 2013 Jun 01; 43(6):608-15. PubMed ID: 23585687
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG).
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):684-90. PubMed ID: 20932658
    [Abstract] [Full Text] [Related]

  • 6. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
    Hsu FM, Lin CC, Lee JM, Chang YL, Hsu CH, Tsai YC, Lee YC, Cheng JC.
    J Surg Oncol; 2008 Jul 01; 98(1):34-41. PubMed ID: 18449912
    [Abstract] [Full Text] [Related]

  • 7. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma.
    Chen J, Pan J, Liu J, Li J, Zhu K, Zheng X, Chen M, Chen M, Liao Z.
    Int J Radiat Oncol Biol Phys; 2013 Jul 15; 86(4):671-7. PubMed ID: 23773390
    [Abstract] [Full Text] [Related]

  • 8. Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after chemoradiotherapy.
    Chao YK, Wu YC, Liu YH, Tseng CK, Chang HK, Hsieh MJ, Chu Y, Liu HP.
    J Surg Oncol; 2010 Aug 01; 102(2):158-62. PubMed ID: 20648587
    [Abstract] [Full Text] [Related]

  • 9. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):691-7. PubMed ID: 20888705
    [Abstract] [Full Text] [Related]

  • 10. [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
    Jiang YY, Wu SX, Zhang P, Xie CY, Wang J, Sun CC.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 12; 88(31):2171-4. PubMed ID: 19080664
    [Abstract] [Full Text] [Related]

  • 11. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study.
    Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, Nakagawa K.
    Radiat Oncol; 2015 Aug 14; 10():171. PubMed ID: 26269033
    [Abstract] [Full Text] [Related]

  • 12. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus.
    Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T.
    Radiother Oncol; 2009 Aug 14; 92(2):266-9. PubMed ID: 18952308
    [Abstract] [Full Text] [Related]

  • 13. Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
    Kim JY, Kim JY, Kim JH, Yoon MS, Kim J, Kim YS.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):741-7. PubMed ID: 22898382
    [Abstract] [Full Text] [Related]

  • 14. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H.
    Int J Clin Oncol; 2019 Jan 01; 24(1):60-67. PubMed ID: 30109544
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.
    Cancer Chemother Pharmacol; 2012 Mar 01; 69(3):655-63. PubMed ID: 21968953
    [Abstract] [Full Text] [Related]

  • 16. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.
    Fernandes AT, Shen J, Finlay J, Mitra N, Evans T, Stevenson J, Langer C, Lin L, Hahn S, Glatstein E, Rengan R.
    Radiother Oncol; 2010 May 01; 95(2):178-84. PubMed ID: 20356642
    [Abstract] [Full Text] [Related]

  • 17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 18. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
    Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, Hsu CH, Lin CC, Cheng JC, Wang YH, Chuang TH, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee YC.
    Ann Surg Oncol; 2011 Jul 15; 18(7):2066-73. PubMed ID: 21298351
    [Abstract] [Full Text] [Related]

  • 19. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.
    Ann Surg Oncol; 2014 Jul 15; 21(7):2361-8. PubMed ID: 24623035
    [Abstract] [Full Text] [Related]

  • 20. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):420-7. PubMed ID: 22365621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.